Fig. 6. Mebendazole (MBZ) enhanced DNA damage by hindering the recruitment of ATM and DNA-PKcs in the nucleus.
(A, B) The alternation of the cellular location and protein levels of γH2AX in CML cells after treatment with MBZ for 24 h was screened by immunofluorescence and western blot. The scale bar represents 10 μm. (C) The levels of ROS were evaluated by FCM. *p < 0.05 vs. the control group. (D) The expression levels of DNA repair protein ATM and DNA-PKcs were assessed by western blot. (E, F) Nuclear and cytoplasmic protein extraction assay was performed and followed by western blot to analyze the cellular accumulation of ATM (E) and DNA-PKcs (F) in the cytoplasm (C) and nucleus (N) in K562/G01 cells. ATM, ataxia-telangiectasia mutated; DNA-PKcs, DNA-dependent protein kinase; CML, chronic myeloid leukemia; ROS, reactive oxygen species; FCM, flow cytometry; ns, no significance.
© Korean J Physiol Pharmacol
